NAA40: A Potential Drug Target Or Biomarker (G79829)

Target Name: NAA40

NCBI ID: G79829

NAA40

NAA40: A Potential Drug Target Or Biomarker

NAA40, also known as N-alpha-acetyltransferase 40, is an enzyme that plays a crucial role in the production of collagen, a protein that is found in the skin, hair, nails, and bones. The NAA40 enzyme is critical for the production of this protein, and any changes in its function have been linked to various diseases, including cancer, osteoporosis, and skin conditions.

Recent studies have also suggested that NAA40 may have potential as a drug target or biomarker. For example, some researchers have found that inhibiting the activity of NAA40 has been shown to enhance the effectiveness of certain cancer treatments. Additionally, studies have shown that high levels of NAA40 have been associated with an increased risk of certain diseases, such as heart disease and diabetes.

The NAA40 enzyme has four different variants, including transcript variant 1. These variants have been shown to have different levels of activity, with transcript variant 1 being the most active. The catalytic subunit of NAA40 is the N-alpha-acetyltransferase domain, which is responsible for the acetylation of specific amino acids on the target protein.

The N-alpha-acetyltransferase domain is a key region of the NAA40 enzyme that allows it to bind to its target protein. This domain has been shown to have a specificity of around 50% for its target protein, which is known as the collagen protein . The specificity of the N-alpha-acetyltransferase domain has been optimized through various structural studies, such as crystallography and X-ray crystallography, to enhance its binding affinity.

One of the challenges in studying NAA40 is its expression level, as the enzyme is produced in low abundance. However, researchers have been able to increase the expression of NAA40 through various means, such as transfection of the enzyme into cells or the use of RNA interference to reduce its production. Once the NAA40 enzyme is expressed, it can be purified and used for various biochemical and biophysical studies, including the determination of its catalytic activity, stability, and interactions with other proteins.

In addition to its use as a drug target or biomarker, NAA40 has also been studied for its potential role in the development and progression of various diseases. For example, some researchers have found that individuals with certain genetic variations in the NAA40 gene are at an increased risk of developing certain diseases, such as cancer and cardiovascular disease. Additionally, studies have shown that alterations in NAA40 expression levels have been associated with the development of various diseases, including heart failure, neurodegenerative diseases, and diabetes.

In conclusion, NAA40 is an enzyme that plays a critical role in the production of collagen, a protein that is essential for various physiological functions. Recent studies have also suggested that NAA40 may have potential as a drug target or biomarker, and further research is needed to fully understand its functions and its potential as a therapeutic agent.

Protein Name: N-alpha-acetyltransferase 40, NatD Catalytic Subunit

Functions: N-alpha-acetyltransferase that specifically mediates the acetylation of the N-terminal residues of histones H4 and H2A (PubMed:21935442, PubMed:25619998). In contrast to other N-alpha-acetyltransferase, has a very specific selectivity for histones H4 and H2A N-terminus and specifically recognizes the 'Ser-Gly-Arg-Gly sequence' (PubMed:21935442, PubMed:25619998). Acts as a negative regulator of apoptosis (PubMed:26666750). May play a role in hepatic lipid metabolism (By similarity)

The "NAA40 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAA40 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets